Potential interaction between warfarin and dicloxacillin

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1402-1407

  Mailloux, Allan T ^a   Gidal, Barry E ^a   Sorkness, Christine A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPRAZOLAM; AMITRIPTYLINE; CAPTOPRIL; DICLOXACILLIN; DIGOXIN; DILTIAZEM; ESTAZOLAM; FUROSEMIDE; GLYCERYL TRINITRATE; IBUPROFEN; ISOSORBIDE DINITRATE; ISPAGULA; LEVOTHYROXINE; PARACETAMOL; POTASSIUM CHLORIDE; PROPRANOLOL; SALBUTAMOL; SUCRALFATE; VERAPAMIL; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; DRUG EFFECT; HEART VALVE PROSTHESIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM;

EID: 0030448816     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001208     Document Type: Article

References (28)

1. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. Ann Intern Med 1984;100:527-9.
2. Davis RL, Berman W, Wernly JA, Kelly HW. Warfarin-nafcillin interaction. J Pediatr 1991;118:300-3.
3. Fraser GL, Miller M, Kane K. Warfarin resistance associated with nafcillin therapy. Am J Med 1989;87:237-8.
4. Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. DICP Ann Pharmacother 1991;25:598-600.
5. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm 1987;6:804-6.
6. Taylor AT, Pritchard DC, Goldstein AO, Fletcher JL. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994;39:182-5.
7. Banfield C, Roland M. Stereospecific high-performance liquid Chromatographic analysis of warfarin in plasma. J Pharm Sci 1983;72:921-4.
8. Black DJ, Kunze KL, Wienekers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarin-fluconazole, part II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-7.
9. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992;5:54-9.
10. Breckenridge A, Orne M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-30.
11. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.
12. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974;53:1607-17.
13. Banfield C, O'Reilly R, Chan E, Roland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. BrJ Clin Pharmacol 1983;16:669-75.
14. Colquhoun MC, Daly M, Stewart P, Beeley L. Interaction between warfarin and tniconazole oral gel (letter). Lancet 1987;1:695-6.
15. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51:656-67.
16. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, et al. The warfarin-sulfmpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;39:15-24.
17. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5.
18. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295:354-7.
19. Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between (iclopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995;17:33-8.
20. Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986;21:271-7.
21. Toon S, Hopkins KJ, Garstang FM, Diquet B, Gill TS, Rowland M. The warfarin-cimetidine interaction: stereochemical considerations. Br J Clin Pharmacol 1986;21:245-6.
22. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176-84.
23. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987;42:33-41.
24. Abernethy DR, Kaminsky LS, Dickinson TH. Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 1991;257:411-5.
25. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51:398-407.
26. Hansten PD, Horn JR. Drug interaction mechanisms and clinical characteristics. In: Hansten PD, Horn JR, Koda-Kimble MA, Young LY, eds. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, 1993:1-24.
27. Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978;5:437-40.
28. Leppik IE, Fisher J, Kriel R, Sawchuk RJ. Altered phenytoin clearance with febrile illness. Neurology 1986;36:1367-70.